This is a phase IV, randomized, single-blind, single-center study comparing calculated total
blood loss, surgical drain output and hematoma formation in patients who receive 2 doses of
Tranexamic Acid (TXA) versus control group undergoing revision total shoulder arthroplasty.
Patients will be randomized to either receive 2 doses of IV TXA, first dose prior to surgical
incision and second dose given 3 hours later or to the control group, where no TXA will be
administered.